Dysregulation of miRNA in chronic hepatitis B is associated with hepatocellular carcinoma risk after nucleos(t)ide analogue treatment.

[1]  K. Hayashi,et al.  Cumulative incidence and risk factors for the development of hepatocellular carcinoma in patients with chronic hepatitis B who achieved sustained disappearance of viremia by nucleos(t)ide analog treatment , 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

[2]  Q. Dong,et al.  MicroRNA profile in HBV-induced infection and hepatocellular carcinoma , 2017, BMC Cancer.

[3]  Xiaolong Liu,et al.  MicroRNA-140-5p inhibits hepatocellular carcinoma by directly targeting the unique isomerase Pin1 to block multiple cancer-driving pathways , 2017, Scientific Reports.

[4]  M. Hsiao,et al.  Dysregulation of RUNX2/Activin-A Axis upon miR-376c Downregulation Promotes Lymph Node Metastasis in Head and Neck Squamous Cell Carcinoma. , 2016, Cancer research.

[5]  Min Liu,et al.  Long non-coding RNA Unigene56159 promotes epithelial-mesenchymal transition by acting as a ceRNA of miR-140-5p in hepatocellular carcinoma cells. , 2016, Cancer letters.

[6]  S. Yuan,et al.  MicroRNA-98 acts as a tumor suppressor in hepatocellular carcinoma via targeting SALL4 , 2016, Oncotarget.

[7]  K. Takayama,et al.  TACC2 (transforming acidic coiled‐coil protein 2) in breast carcinoma as a potent prognostic predictor associated with cell proliferation , 2016, Cancer medicine.

[8]  W. Guo,et al.  MiR‐199a‐5p is negatively associated with malignancies and regulates glycolysis and lactate production by targeting hexokinase 2 in liver cancer , 2015, Hepatology.

[9]  M. Bouchard,et al.  Hepatitis B virus and microRNAs: Complex interactions affecting hepatitis B virus replication and hepatitis B virus-associated diseases. , 2015, World journal of gastroenterology.

[10]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[11]  Ke Chen,et al.  Regulation of the microRNA processor DGCR8 by hepatitis B virus proteins via the transcription factor YY1 , 2015, Archives of Virology.

[12]  Ying Shi,et al.  MiR-148b suppresses cell proliferation and invasion in hepatocellular carcinoma by targeting WNT1/β-catenin pathway , 2015, Scientific Reports.

[13]  Yang Zhang,et al.  microRNA-146a inhibits cancer metastasis by downregulating VEGF through dual pathways in hepatocellular carcinoma , 2015, Molecular Cancer.

[14]  U. Pastorino,et al.  Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction , 2014, Cell Death and Disease.

[15]  Chih-Yang Huang,et al.  A putative novel protein, DEPDC1B, is overexpressed in oral cancer patients, and enhanced anchorage-independent growth in oral cancer cells that is mediated by Rac1 and ERK , 2014, Journal of Biomedical Sciences.

[16]  T. Albert,et al.  Cyclin-Dependent Kinase 7 Controls mRNA Synthesis by Affecting Stability of Preinitiation Complexes, Leading to Altered Gene Expression, Cell Cycle Progression, and Survival of Tumor Cells , 2014, Molecular and Cellular Biology.

[17]  H. Guan,et al.  DEPDC1B enhances migration and invasion of non-small cell lung cancer cells via activating Wnt/β-catenin signaling. , 2014, Biochemical and biophysical research communications.

[18]  A. Butt,et al.  Expression profiling of serum microRNA-101 in HBV-associated chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma , 2014, Cancer biology & therapy.

[19]  V. Cicinnati,et al.  MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity. , 2014, Journal of hepatology.

[20]  Hussein H. Aly,et al.  Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP. , 2014, Biochemical and biophysical research communications.

[21]  Zhao-You Tang,et al.  MiR-146a enhances angiogenic activity of endothelial cells in hepatocellular carcinoma by promoting PDGFRA expression. , 2013, Carcinogenesis.

[22]  Eun-Kyoung Breuer,et al.  Transforming acidic coiled-coil proteins (TACCs) in human cancer. , 2013, Cancer letters.

[23]  Yoshiyuki Suzuki,et al.  Long‐term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection , 2013, Hepatology.

[24]  R. Chang,et al.  MicroRNA‐140‐5p suppresses tumor growth and metastasis by targeting transforming growth factor β receptor 1 and fibroblast growth factor 9 in hepatocellular carcinoma , 2013, Hepatology.

[25]  Zhongjun Wu,et al.  miR-101 is down-regulated by the hepatitis B virus x protein and induces aberrant DNA methylation by targeting DNA methyltransferase 3A. , 2013, Cellular signalling.

[26]  S. Giordano,et al.  MicroRNAs: New tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? , 2013, Hepatology.

[27]  Jaw-Town Lin,et al.  Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection. , 2012, JAMA.

[28]  Hua Tang,et al.  Correlation between hepatitis B virus protein and microRNA processor Drosha in cells expressing HBV. , 2012, Antiviral research.

[29]  H. El‐Serag,et al.  Epidemiology of viral hepatitis and hepatocellular carcinoma. , 2012, Gastroenterology.

[30]  Young Woo Kim,et al.  Farnesoid X receptor protects hepatocytes from injury by repressing miR-199a-3p, which increases levels of LKB1. , 2012, Gastroenterology.

[31]  Y. Homma,et al.  TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancer. , 2012, Molecular endocrinology.

[32]  M. Toyota,et al.  Upregulation of miR-196a and HOTAIR drive malignant character in gastrointestinal stromal tumors. , 2012, Cancer research.

[33]  Zheng Wang,et al.  Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  A. Huang,et al.  Hepatitis B virus and hepatocellular carcinoma at the miRNA level. , 2011, World journal of gastroenterology.

[35]  Xing-Xing He,et al.  MiR-192 inhibits nucleotide excision repair by targeting ERCC3 and ERCC4 in HepG2.2.15 cells. , 2011, Biochemical and biophysical research communications.

[36]  Y. Surh,et al.  Ibulocydine Is a Novel Prodrug Cdk Inhibitor That Effectively Induces Apoptosis in Hepatocellular Carcinoma Cells* , 2011, The Journal of Biological Chemistry.

[37]  Li Lin,et al.  Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. , 2011, Cancer cell.

[38]  Yoshiki Murakami,et al.  The Progression of Liver Fibrosis Is Related with Overexpression of the miR-199 and 200 Families , 2011, PloS one.

[39]  H. Kung,et al.  Hsa‐let‐7g inhibits proliferation of hepatocellular carcinoma cells by downregulation of c‐Myc and upregulation of p16INK4A , 2011, International journal of cancer.

[40]  Thomas D. Schmittgen,et al.  miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines. , 2010, Biochemical and biophysical research communications.

[41]  X. Chen,et al.  Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. , 2010, Cancer research.

[42]  Xin Li,et al.  Suppression of hepatitis B virus replication by microRNA-199a-3p and microRNA-210. , 2010, Antiviral research.

[43]  G. Gerken,et al.  Role of microRNA-199a-5p and discoidin domain receptor 1 in human hepatocellular carcinoma invasion , 2010, Molecular Cancer.

[44]  Lewis R. Roberts,et al.  Hepatocellular carcinoma: a global view , 2010, Nature Reviews Gastroenterology &Hepatology.

[45]  W. Sung,et al.  Lethal-7 is down-regulated by the hepatitis B virus x protein and targets signal transducer and activator of transcription 3. , 2010, Journal of hepatology.

[46]  Yue Wang,et al.  Down‐regulated microRNA‐152 induces aberrant DNA methylation in hepatitis B virus–related hepatocellular carcinoma by targeting DNA methyltransferase 1 , 2010, Hepatology.

[47]  C. Croce,et al.  MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. , 2010, Cancer research.

[48]  X. Wang,et al.  Let-7g targets collagen type I alpha2 and inhibits cell migration in hepatocellular carcinoma. , 2010, Journal of hepatology.

[49]  K. Horimoto,et al.  Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma , 2009, Hepatology.

[50]  Jian-Rong Yang,et al.  MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. , 2009, Cancer research.

[51]  Jian-Rong Yang,et al.  A functional polymorphism in the miR-146a gene is associated with the risk for hepatocellular carcinoma. , 2008, Carcinogenesis.

[52]  M. Toyota,et al.  Frequent epigenetic inactivation of SFRP genes in hepatocellular carcinoma , 2008, Journal of Gastroenterology.

[53]  J. Ihle,et al.  The Centrosomal, Putative Tumor Suppressor Protein TACC2 Is Dispensable for Normal Development, and Deficiency Does Not Lead to Cancer , 2004, Molecular and Cellular Biology.

[54]  Yoshiaki Miyauchi,et al.  Cyclins and cyclin‐dependent kinases: Comparative study of hepatocellular carcinoma versus cirrhosis , 2003, Hepatology.

[55]  I. Mian,et al.  AZU-1: a candidate breast tumor suppressor and biomarker for tumor progression. , 2000, Molecular biology of the cell.

[56]  T. Therneau,et al.  Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.